FDG-PET is a good biomarker of both early response and acquired resistance in BRAF(V600) mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

BACKGROUND: The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic melanoma in patients harboring BRAF(V600) mutations. Currently, dual BRAF and MEK inhibition are ongoing in clinical trials with the goal of overcoming the acquired resistance that has unfortunate...

Descripción completa

Detalles Bibliográficos
Autores principales: Baudy, Andreas R, Dogan, Taner, Flores-Mercado, Judith E, Hoeflich, Klaus P, Su, Fei, van Bruggen, Nicholas, Williams, Simon-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405466/
https://www.ncbi.nlm.nih.gov/pubmed/22651703
http://dx.doi.org/10.1186/2191-219X-2-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405466/
https://www.ncbi.nlm.nih.gov/pubmed/22651703
http://dx.doi.org/10.1186/2191-219X-2-22

Ejemplares similares